FDA 483 - Aptuit (Oxford) Ltd. - August 22, 2025

Between August 18 and August 22, 2025, the U.S. Food and Drug Administration (FDA) conducted an inspection of Aptuit (Oxford) Ltd, a manufacturer of active pharmaceutical ingredients (APIs) and excipients located in Abingdon, United Kingdom. The inspection resulted in the issuance of Form 483, which identifies seven major observations concerning the firm"s quality management and testing protocols. The primary violations involve a significant failure of the quality unit to provide oversight, including the release of API batches to the market without confirming safety levels for specific impurities. Furthermore, the company failed to thoroughly investigate customer complaints regarding products that exceeded specification limits and did not implement corrective actions to prevent recurrence. The FDA also highlighted critical deficiencies in microbiological controls. The company utilized an unaccredited contract laboratory that did not follow international standards for testing water systems and APIs intended for sterile products. Even after identifying these deficiencies, the firm continued to rely on the laboratory"s questionable results for product release. Other issues included a lack of validated microbiological test methods, inadequate identification testing for raw materials, and inconsistent sampling procedures. These observations represent preliminary findings and not a final agency determination. Aptuit is expected to respond to the FDA with a comprehensive plan for corrective and preventive actions to address these systemic quality failures.